“Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC – Study Drug for Early Etiotropic Therapy of Coronavirus Infection Caused by the SARS-CoV-2 Virus, Using Heavy-chain Humanized Monoclonal Antibodies, After Single Administration to Adult Patients”.

ingentiumby ingentium

In Discovery News.

“Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC – Study Drug for Early Etiotropic Therapy of Coronavirus Infection Caused by the SARS-CoV-2 Virus, Using Heavy-chain Humanized Monoclonal Antibodies, After Single Administration to Adult Patients”.

Publication date: Sep 02, 2025

A two-stage open-label, prospective, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity study with participation of healthy volunteers in three dose-escalation groups and patients with a confirmed diagnosis of COVID-19.

Concepts Keywords
Childbearing Administration
Coronavirus Blood
Immunobiological Covid
Obesity Diseases
Drug
History
Inclusion
Participation
Potential
Presence
Sars
Stage
Study
Test
Volunteer

Semantics

Type Source Name
disease MESH Coronavirus Infection
disease MESH COVID-19
disease IDO history
disease IDO blood
disease MESH abnormalities
disease IDO assay
disease MESH hepatitis B
pathway KEGG Hepatitis B
disease MESH syphilis
drug DRUGBANK Ethanol
drug DRUGBANK Oxygen
disease MESH death
disease MESH obesity
disease IDO immunodeficiency
disease MESH diabetes mellitus
disease MESH cardiovascular diseases
disease MESH chronic kidney disease
disease MESH diseases liver
disease MESH infectious diseases
disease MESH non-infectious diseases
disease MESH chronic diseases
disease MESH mental illnesses
disease IDO facility
disease MESH Autoimmune diseases
disease IDO cell
disease MESH acquired immunodeficiency syndrome
disease MESH erythema
disease MESH toxic epidermal necrolysis
disease MESH angioedema
disease MESH eczema
disease MESH serum sickness
disease MESH hypersensitivity
drug DRUGBANK Dextrose unspecified form
disease MESH malignant neoplasms
disease MESH carcinomas
disease MESH metastasis
disease IDO intervention
disease MESH concomitant disease
disease MESH contraindication
disease MESH Respiratory failure
disease MESH Septic shock
disease MESH infection
disease MESH comorbidity
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH drug addiction

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *